Prelude Therapeutics Inc (PRLD)
Prelude Therapeutics Inc. is a clinical-stage precision oncology company focused on discovering and developing new cancer medicines for patients with limited treatment options. Its pipeline includes a JAK2V617F program aimed at myeloproliferative neoplasms such as myelofibrosis, polycythemia vera, and essential thrombocythemia; a KAT6A program being developed for advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates for myelofibrosis and essential thrombocythemia. The company also has a collaboration with AbCellera Biologics to support the discovery, development, and commercialization of degrader antibody conjugates. Incorporated in 2016, Prelude Therapeutics is based in Wilmington, Delaware, and its common stock trades on the NASDAQ under the symbol PRLD.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-PRLD
|
$3.98
|
-4.0% Downside
|
Fair
|
$8
|
93.2% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 19, 2026
|
-5.3x
|
6.8x
|
24.5x
|
402.7 M
|
346.3 M
|
4.2%
|
27.8%
|
-5.8
|
—
|
56.3%
|
